Taken together, these data support our hypothesis that Onc-p53 confers venetoclax resistance and that simultaneous inhibition of BCL-2 and Onc-p53 enhances anticancer activity in a subset of SCLC-A and SCLC-P. The gene discussed is BCL2; the disease is small cell lung carcinoma.